“To address this critical unmet need, a next-generation HSP Subunit Vaccine has been developed through collaborative research ...

Bhubaneswar and Institute of Life Sciences (ILS) along with National Research Development Corporation (NRDC) on Monday signed ...

The agreement paves the way for technology transfer and potential commercialisation of a promising new vaccine candidate, ...

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS) along with the ...

The vaccine triggers strong immune responses against Mycobacterium tuberculosis and is licensed for commercial development to ...

Bhubaneswar and Institute of Life Sciences (ILS) along with National Research Development Corporation (NRDC) o ...

Three Indian research institutes have signed an agreement with TechInvention Lifecare Limited for the technology transfer and future commercialisation of a novel TB vaccine candidate<br />The Indian ...

A new TB vaccine for adolescents and adults, developed by IIT and ILS Bhubaneswar, is set for commercialisation.

Bhubaneswar: The Bhubaneswar-based Indian Institute of Technology (IIT), the Institute of Life Sciences (ILS), along with the ...

The Indian Institute of Technology and the Institute of Life Sciences, in partnership with TechInvention Lifecare and the National Research Development Corporation, are advancing a novel TB vaccine.

The HSP Subunit Vaccine candidate, jointly developed by the Institute of Life Sciences (ILS), Bhubaneswar, and the Indian Institute of Technology (IIT) Bhubaneswar, marks a significant advancement in ...

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by the WHO. Ending the TB epidemic by 2030 is a key global health ...